drugset / Trial / NCT05010460

Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting

NCT05010460

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Acute kidney injury is a frequent complication after coronary artery bypass grafting (CABG). Roxadustat is a prolyl hydroxylase inhibitor (PHI) which can stabilize hypoxia-inducible factor (HIF) and improve the hypoxic tolerance of tissues. Roxadustat has shown effect in reducing acute kidney injury in animal studies. This study aims to evaluate the efficacy of administration of Roxadustat before surgery in the prevention of acute kidney injury after CABG.

Timeline

Start
2021-09-30
Primary completion
2025-05-20
Completion
2025-05-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Roxadustat Small molecule 100 mg Oral

Indications

No indication recorded.